Citations (123)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Tanveer Sharif, Emma Martell, Cathleen Dai, Mohammad Saleh Ghassemi-Rad, Mark Robert Hanes, Patrick J. Murphy, Nandini N. Margam, Hirendrasinh B. Parmar, Carman A. Giacomantonio, Roy Duncan, Patrick W.K. Lee & Shashi Gujar. (2019) HDAC6 differentially regulates autophagy in stem-like versus differentiated cancer cells. Autophagy 15:4, pages 686-706.
Read now
Read now
Yingzi He, Beier Bao & Huawei Li. (2017) Using zebrafish as a model to study the role of epigenetics in hearing loss. Expert Opinion on Drug Discovery 12:9, pages 967-975.
Read now
Read now
Majid Tafrihi & Roohollah Nakhaei Sistani. (2017) E-Cadherin/β-Catenin Complex: A Target for Anticancer and Antimetastasis Plants/Plant-derived Compounds. Nutrition and Cancer 69:5, pages 702-722.
Read now
Read now
Gun-Il Im & You-Jeong Choi. (2013) Epigenetics in osteoarthritis and its implication for future therapeutics. Expert Opinion on Biological Therapy 13:5, pages 713-721.
Read now
Read now
Nicholas M Njuguna, Dennis S B Ongarora & Kelly Chibale. (2012) Artemisinin derivatives: a patent review (2006 – present). Expert Opinion on Therapeutic Patents 22:10, pages 1179-1203.
Read now
Read now
Yong Fang, Yi Hu, Peng Wu, Beibei Wang, Yuan Tian, Xi Xia, Qinghua Zhang, Tong Chen, Xuefeng Jiang, Quanfu Ma, Gang Xu, Shixuan Wang, Jianfeng Zhou, Ding Ma & Li Meng. (2011) Synergistic Efficacy in Human Ovarian Cancer Cells by Histone Deacetylase Inhibitor TSA and Proteasome Inhibitor PS-341. Cancer Investigation 29:4, pages 247-252.
Read now
Read now
Dominik Sebastian Mestel, Marc Beyer, Markus Möbs, Matthias Steinhoff, Wolfram Sterry & Chalid Assaf. (2008) Zanolimumab, a human monoclonal antibody targeting CD4 in the treatment of mycosis fungoides and Sézary syndrome. Expert Opinion on Biological Therapy 8:12, pages 1929-1939.
Read now
Read now
Dominik Sebastian Mestel, Chalid Assaf, Matthias Steinhoff, Marc Beyer, Markus Moebs & Wolfram Sterry. (2008) Emerging drugs in cutaneous T cell lymphoma. Expert Opinion on Emerging Drugs 13:2, pages 345-361.
Read now
Read now
Walid Rasheed, Mark Bishton, Ricky W Johnstone & H Miles Prince. (2008) Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Review of Anticancer Therapy 8:3, pages 413-432.
Read now
Read now
Articles from other publishers (114)
Michael Kohr, Niklas Papenkordt, Manfred Jung & Uli Kazmaier. (2023) Total synthesis and biological evaluation of histone deacetylase inhibitor WF-3161. Organic & Biomolecular Chemistry 21:21, pages 4382-4387.
Crossref
Crossref
Eri Watanabe, Akira Yokoi, Kosuke Yoshida, Mai Sugiyama, Masami Kitagawa, Kimihiro Nishino, Eiko Yamamoto, Kaoru Niimi, Yusuke Yamamoto & Hiroaki Kajiyama. (2022) Drug library screening identifies histone deacetylase inhibition as a novel therapeutic strategy for choriocarcinoma. Cancer Medicine 12:4, pages 4543-4556.
Crossref
Crossref
Yueyuan Zhong, Mingdong Li, Shihui Guo, Minhua Li, Zitong Cao, Xueyao Luo, Jianhong Liu, Runzhang Liang, Yingqi Shao, Yue Yang, Xinqia Chen, Chuzhong Wei, Weijun Ling, Xiao Zhu & Yongmei Huang. (2023) Histone Deacetylase 1 Expression and Regulatory Network in Lung Adenocarcinoma Based on Data Mining and Implications for Targeted Treatment. Journal of Oncology 2023, pages 1-16.
Crossref
Crossref
Appu Rathinavelu & Umamaheswari Natarajan. 2023. Epigenetics in Organ Specific Disorders. Epigenetics in Organ Specific Disorders
63
97
.
Skye Hsin-Hsien Yeh, Ming Hsien Lin, I. I. Leo Garcia Flores, Uday Mukhopadhyay, Danial Young, Kazuma Ogawa, Jeong-Hwan Jeong, William Tong, Juri G. Gelovani & Nobuyoshi Fukumitsu. (2021) In Vivo Evaluation of the Combined Anticancer Effects of Cisplatin and SAHA in Nonsmall Cell Lung Carcinoma Using [18F]FAHA and [18F]FDG PET/CT Imaging. Molecular Imaging 2021, pages 1-11.
Crossref
Crossref
Sara Daniela Gomes, Cláudia Suellen Oliveira, João Azevedo-Silva, Marta R. Casanova, Judite Barreto, Helena Pereira, Susana R. Chaves, Lígia R. Rodrigues, Margarida Casal, Manuela Côrte-Real, Fátima Baltazar & Ana Preto. (2020) The Role of Diet Related Short-Chain Fatty Acids in Colorectal Cancer Metabolism and Survival: Prevention and Therapeutic Implications. Current Medicinal Chemistry 27:24, pages 4087-4108.
Crossref
Crossref
Brianna Burke, Catherine Eden, Cynthia Perez, Alex Belshoff, Spencer Hart, Lourdes Plaza-Rojas, Michael Delos Reyes, Kushal Prajapati, Christina Voelkel-Johnson, Elizabeth Henry, Gopal Gupta & José Guevara-Patiño. (2020) Inhibition of Histone Deacetylase (HDAC) Enhances Checkpoint Blockade Efficacy by Rendering Bladder Cancer Cells Visible for T Cell-Mediated Destruction. Frontiers in Oncology 10.
Crossref
Crossref
Sebastian N. Knoppert, Floris A. Valentijn, Tri Q. Nguyen, Roel Goldschmeding & Lucas L. Falke. (2019) Cellular Senescence and the Kidney: Potential Therapeutic Targets and Tools. Frontiers in Pharmacology 10.
Crossref
Crossref
Alexander M. Cryer & Andrew J. Thorley. (2019) Nanotechnology in the diagnosis and treatment of lung cancer. Pharmacology & Therapeutics 198, pages 189-205.
Crossref
Crossref
Masumeh Sanaei & Fraidoon Kavoosi. (2019) Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers. Advanced Biomedical Research 8:1, pages 63.
Crossref
Crossref
Yin-Wei Cheng, Lian-Di Liao, Qian Yang, Yang Chen, Ping-Juan Nie, Xiao-Jun Zhang, Jian-Jun Xie, Bao-En Shan, Lian-Mei Zhao, Li-Yan Xu & En-Min Li. (2018) The histone deacetylase inhibitor panobinostat exerts anticancer effects on esophageal squamous cell carcinoma cells by inducing cell cycle arrest. Cell Biochemistry and Function 36:8, pages 398-407.
Crossref
Crossref
Vera Miranda-Gonçalves, Ana Lameirinhas, Rui Henrique & Carmen Jerónimo. (2018) Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets. Frontiers in Genetics 9.
Crossref
Crossref
Rekha Sangwan, Remya Rajan & Pintu Kumar Mandal. (2018) HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors. European Journal of Medicinal Chemistry 158, pages 620-706.
Crossref
Crossref
Mohammad Alzrigat, Alba Atienza Párraga & Helena Jernberg-Wiklund. (2018) Epigenetics in multiple myeloma: From mechanisms to therapy. Seminars in Cancer Biology 51, pages 101-115.
Crossref
Crossref
Asadollah Mohammadi, Atefeh Sharifi, Reza Pourpaknia, Saeed Mohammadian & Amirhossein Sahebkar. (2018) Manipulating macrophage polarization and function using classical HDAC inhibitors: Implications for autoimmunity and inflammation. Critical Reviews in Oncology/Hematology 128, pages 1-18.
Crossref
Crossref
Shiv Prakash Verma, Ayushi Agarwal & Parimal Das. (2018) Sodium butyrate induces cell death by autophagy and reactivates a tumor suppressor gene DIRAS1 in renal cell carcinoma cell line UOK146. In Vitro Cellular & Developmental Biology - Animal 54:4, pages 295-303.
Crossref
Crossref
Xiaochen Yan, Bo Pan, Tiewei Lv, Lingjuan Liu, Jing Zhu, Wen Shen, Xupei Huang & Jie Tian. (2017) Inhibition of histone acetylation by curcumin reduces alcohol-induced fetal cardiac apoptosis. Journal of Biomedical Science 24:1.
Crossref
Crossref
Zakir Khan, Abdul Arif Khan, Hariom Yadav, Godavarthi B. K. S. Prasad & Prakash Singh Bisen. (2017) Survivin, a molecular target for therapeutic interventions in squamous cell carcinoma. Cellular & Molecular Biology Letters 22:1.
Crossref
Crossref
Sumana Venkat, Dharma Theja Nannapaneni, Caroline Gregory, Qinglei Gan, Matt McIntosh & Chenguang Fan. (2017)
Genetically encoding thioacetyl-lysine as a non-deacetylatable analog of lysine acetylation in
Escherichia coli
. FEBS Open Bio 7:11, pages 1805-1814.
Crossref
Crossref
Aliasghar Rahimian & Ali Mellati. (2017) The Effect of Histone Hyperacetylation on Viability of Basal-Like Breast Cancer Cells MDA-MB-231. Razavi International Journal of Medicine 5:2.
Crossref
Crossref
Andrea Alpuche-García, Xochitl Dávila-González, Leticia Arregui & Hiram I. Beltrán. (2017) Novel valproic aminophenol amides with enhanced glial cell viability effect. RSC Advances 7:20, pages 12391-12399.
Crossref
Crossref
Phong Trang, Joanne B. Weidhaas & Frank J. Slack. 2017. The Molecular Basis of Human Cancer. The Molecular Basis of Human Cancer
277
286
.
T. A. L. Brevini, G. Pennarossa, E. F. M. Manzoni, C. E. Gandolfi, A. Zenobi & F. Gandolfi. (2016) The quest for an effective and safe personalized cell therapy using epigenetic tools. Clinical Epigenetics 8:1.
Crossref
Crossref
Leslie A. Garrett, Whitfield B. Growdon, Bo R. Rueda & Rosemary Foster. (2016) Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer. Journal of Ovarian Research 9:1.
Crossref
Crossref
Corey A. Carter, Karen Zeman, Regina M. Day, Patrick Richard, Arnold Oronsky, Neil Oronsky, Michelle Lybeck, Jan Scicinski & Bryan Oronsky. (2016) Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies. Oncotarget 7:26, pages 40781-40791.
Crossref
Crossref
Jianguo Feng, Shirong Zhang, Kan Wu, Bing Wang, Jeffrey Y.C. Wong, Hong Jiang, Rujun Xu, Lisha Ying, Haixiu Huang, Xiaoliang Zheng, Xufeng Chen & Shenglin Ma. (2016) Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics 15:5, pages 842-853.
Crossref
Crossref
Bo Ra You & Woo Hyun Park. (2016) Down-Regulation of Thioredoxin1 Is Involved in Death of Calu-6 Lung Cancer Cells Treated With Suberoyl Bishydroxamic Acid. Journal of Cellular Biochemistry 117:5, pages 1250-1261.
Crossref
Crossref
Michaela Angelika Ihle, Sabine Merkelbach‐Bruse, Wolfgang Hartmann, Sebastian Bauer, Nancy Ratner, Hiroshi Sonobe, Jun Nishio, Olle Larsson, Pierre Åman, Florence Pedeutour, Takahiro Taguchi, Eva Wardelmann, Reinhard Buettner & Hans‐Ulrich Schildhaus. (2016) HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat. The Journal of Pathology: Clinical Research 2:2, pages 59-71.
Crossref
Crossref
Somy YoonGwang Hyeon Eom. (2016) HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases. Chonnam Medical Journal 52:1, pages 1.
Crossref
Crossref
Marwa Matboli, Sarah El-Nakeep, Nourhan Hossam, Alaa Habieb, Ahmed EM Azazy, Ali E Ebrahim, Ziad Nagy & Omar Abdel-Rahman. (2016) Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature. World Journal of Gastroenterology 22:26, pages 5896.
Crossref
Crossref
Alice Pasini, Angelo Delmonte, Anna Tesei, Daniele Calistri & Emanuele Giordano. (2015) Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results. Drugs 75:15, pages 1757-1771.
Crossref
Crossref
Manisha Sachan & Manpreet Kaur. (2015) Epigenetic Modifications: Therapeutic Potential in Cancer. Brazilian Archives of Biology and Technology 58:4, pages 526-539.
Crossref
Crossref
John D. Hainsworth, Gedske Daugaard, Thierry Lesimple, Gerdt Hübner, F. Anthony Greco, Michael J. Stahl, Christian Meyer Zum Büschenfelde, Djelila Allouache, Nicolas Penel, Poul Knoblauch & Karim S. Fizazi. (2015) Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial. Cancer 121:10, pages 1654-1661.
Crossref
Crossref
MEIYING JI, EUN JEOUNG LEE, KI BAE KIM, YANGMI KIM, ROHYUN SUNG, SANG-JEON LEE, DON SOO KIM & SEON MEE PARK. (2015) HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells. Oncology Reports 33:5, pages 2299-2308.
Crossref
Crossref
XIAOLI MA, HUA DUAN, JIA LIU, QINGQING MO, CHENGJUAN SUN, DING MA & JIANDONG WANG. (2015) Effect of LIV1 on the sensitivity of ovarian cancer cells to trichostatin A. Oncology Reports 33:2, pages 893-898.
Crossref
Crossref
Mariarosaria Conte, Carmela Dell’Aversana, Rosaria Benedetti, Francesca Petraglia, Annamaria Carissimo, Valeria Belsito Petrizzi, Alfonso Maria D’Arco, Ciro Abbondanza, Angela Nebbioso & Lucia Altucci. (2014) HDAC2 deregulation in tumorigenesis is causally connected to repression of immune modulation and defense escape. Oncotarget 6:2, pages 886-901.
Crossref
Crossref
Hongpeng He, Xuena Liu, Dandan Wang, Yijie Wang, Lei Liu, Hao Zhou, Xuegang Luo, Nan Wang, Bingyan Ji, Yan Luo & Tongcun Zhang. (2014) SAHA inhibits the transcription initiation of HPV18 E6/E7 genes in HeLa cervical cancer cells. Gene 553:2, pages 98-104.
Crossref
Crossref
Murugavel Ponnusamy, Xiaoxu Zhou, Yanli Yan, Jinhua Tang, Evelyn Tolbert, Ting C. Zhao, Rujun Gong & Shougang Zhuang. (2014) Blocking Sirtuin 1 and 2 Inhibits Renal Interstitial Fibroblast Activation and Attenuates Renal Interstitial Fibrosis in Obstructive Nephropathy. Journal of Pharmacology and Experimental Therapeutics 350:2, pages 243-256.
Crossref
Crossref
Yingzi He, Honglin Mei, Huiqian Yu, Shan Sun, Wenli Ni & Huawei Li. (2014) Role of histone deacetylase activity in the developing lateral line neuromast of zebrafish larvae. Experimental & Molecular Medicine 46:5, pages e94-e94.
Crossref
Crossref
YANXIA ZHAO, DANDAN YU, HONGGE WU, HONGLI LIU, HONGXIA ZHOU, RUNXIA GU, RUIGUANG ZHANG, SHENG ZHANG & GANG WU. (2014) Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo. International Journal of Oncology 44:2, pages 451-458.
Crossref
Crossref
F M Frame, D Pellacani, A T Collins, M S Simms, V M Mann, GDD Jones, M Meuth, R G Bristow & N J Maitland. (2013) HDAC inhibitor confers radiosensitivity to prostate stem-like cells. British Journal of Cancer 109:12, pages 3023-3033.
Crossref
Crossref
Xianqin Wang, Mengchun Chen, Congcong Wen, Qingwei Zhang & Jianshe Ma. (2013) Determination of chidamide in rat plasma by LC‐MS and its application to pharmacokinetics study. Biomedical Chromatography 27:12, pages 1801-1806.
Crossref
Crossref
Martin Lübke, Manfred Jung & Günter Haufe. (2013) New histone deacetylase inhibitors based on 4-fluoro-2-amino acid esters: Synthesis and activity. Journal of Fluorine Chemistry 152, pages 144-156.
Crossref
Crossref
Y J Kim, C B Greer, K R Cecchini, L N Harris, D P Tuck & T H Kim. (2013) HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade. Oncogene 32:23, pages 2828-2835.
Crossref
Crossref
Balasubramanian Gopalan, Thanasekaran Ponpandian, Virendra Kachhadia, Kuppusamy Bharathimohan, Radhakrishnan Vignesh, Velaiah Sivasudar, Shridhar Narayanan, Bhonde Mandar, Rajendran Praveen, Nithyanandan Saranya, Sriram Rajagopal & Sridharan Rajagopal. (2013) Discovery of adamantane based highly potent HDAC inhibitors. Bioorganic & Medicinal Chemistry Letters 23:9, pages 2532-2537.
Crossref
Crossref
Shikhar Uttam, Rajan K. Bista, Kevin Staton, Sergey Alexandrov, Serah Choi, Christopher J. Bakkenist, Douglas J. Hartman, Randall E. Brand & Yang Liu. (2013) Investigation of depth-resolved nanoscale structural changes in regulated cell proliferation and chromatin decondensation. Biomedical Optics Express 4:4, pages 596.
Crossref
Crossref
Daisy Corvetta, Olesya Chayka, Samuele Gherardi, Cosimo W. D'Acunto, Sandra Cantilena, Emanuele Valli, Izabela Piotrowska, Giovanni Perini & Arturo Sala. (2013) Physical Interaction between MYCN Oncogene and Polycomb Repressive Complex 2 (PRC2) in Neuroblastoma. Journal of Biological Chemistry 288:12, pages 8332-8341.
Crossref
Crossref
Himashinie V.K. Diyabalanage, Michael L. Granda & Jacob M. Hooker. (2013) Combination therapy: Histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Letters 329:1, pages 1-8.
Crossref
Crossref
B. F. Chu, M. J. Karpenko, Z. Liu, J. Aimiuwu, M. A. Villalona-Calero, K. K. Chan, M. R. Grever & G. A. Otterson. (2012) Phase I study of 5-aza-2′-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 71:1, pages 115-121.
Crossref
Crossref
JUNFEN MA, JIMIN ZHAO, JING LU, YANAN JIANG, HONGYAN YANG, PEI LI, MINGYAO ZHAO, KANGDONG LIU & ZIMING DONG. (2012) Coxsackievirus and adenovirus receptor promotes antitumor activity of oncolytic adenovirus H101 in esophageal cancer. International Journal of Molecular Medicine 30:6, pages 1403-1409.
Crossref
Crossref
Ahmet Korkmaz, Sergio Rosales-Corral & Russel J. Reiter. (2012) Gene regulation by melatonin linked to epigenetic phenomena. Gene 503:1, pages 1-11.
Crossref
Crossref
M.J. Barter, C. Bui & D.A. Young. (2012) Epigenetic mechanisms in cartilage and osteoarthritis: DNA methylation, histone modifications and microRNAs. Osteoarthritis and Cartilage 20:5, pages 339-349.
Crossref
Crossref
Kouji BannoIori Kisu, Megumi Yanokura, Kenta Masuda, Arisa Ueki, Yusuke Kobayashi, Nobuyuki Susumu & Daisuke Aoki. (2012) Epigenetics and genetics in endometrial cancer: new carcinogenic mechanisms and relationship with clinical practice. Epigenomics 4:2, pages 147-162.
Crossref
Crossref
Lei Zhang, Guiying Wang, Lin Wang, Chenlin Song, Ye Leng, Xinhua Wang & Jiuhong Kang. (2011) VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin. Molecular and Cellular Biochemistry 361:1-2, pages 39-45.
Crossref
Crossref
José Christian Machado Ximenes, Emilio Crisóstomo Lima Verde, Maria da Graça Naffah-Mazzacoratti & Glauce Socorro de Barros Viana. (2012) Valproic Acid, a Drug with Multiple Molecular Targets Related to Its Potential Neuroprotective Action. Neuroscience and Medicine 03:01, pages 107-123.
Crossref
Crossref
P.A. Zucali, G.L. Ceresoli, F. De Vincenzo, M. Simonelli, E. Lorenzi, L. Gianoncelli & A. Santoro. (2011) Advances in the biology of malignant pleural mesothelioma. Cancer Treatment Reviews 37:7, pages 543-558.
Crossref
Crossref
Jun-Seop Shin, Byoung-Hoon Min, Jong-Yeon Lim, Byoung-Keun Kim, Hyun-Ju Han, Kun-Ho Yoon, Sang-Joon Kim & Chung-Gyu Park. (2011) Novel Culture Technique Involving an Histone Deacetylase Inhibitor Reduces the Marginal Islet Mass to Correct Streptozotocin-Induced Diabetes. Cell Transplantation 20:9, pages 1321-1332.
Crossref
Crossref
C. Song, A. Kanthasamy, H. Jin, V. Anantharam & A.G. Kanthasamy. (2011) Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration. NeuroToxicology 32:5, pages 586-595.
Crossref
Crossref
Michael Kraft, Ion Cristian Cirstea, Anne Kathrin Voss, Tim Thomas, Ina Goehring, Bilal N. Sheikh, Lavinia Gordon, Hamish Scott, Gordon K. Smyth, Mohammad Reza Ahmadian, Udo Trautmann, Martin Zenker, Marco Tartaglia, Arif Ekici, André Reis, Helmuth-Guenther Dörr, Anita Rauch & Christian Thomas Thiel. (2011) Disruption of the histone acetyltransferase MYST4 leads to a Noonan syndrome–like phenotype and hyperactivated MAPK signaling in humans and mice. Journal of Clinical Investigation 121:9, pages 3479-3491.
Crossref
Crossref
Paolo Andrea Zucali, Rita De Sanctis, Fabio De Vincenzo, Matteo Simonelli, Elena Lorenzi, Matteo Perrino & Armando Santoro. (2011) Treatment of malignant pleural mesothelioma: current status and future directions. Clinical Investigation 1:7, pages 999-1018.
Crossref
Crossref
Srividya Viswanathan, Sarah Carothers & Bhuvaneswari Ramaswamy. (2011) Therapeutic potential of histone deacetylase inhibitors for breast cancer. Clinical Investigation 1:4, pages 519-532.
Crossref
Crossref
Yoshiyuki Hattori, Yasuo Nagaoka, Manami Kubo, Haruka Yamasaku, Yuta Ishii, Hiroko Okita, Hiroki Nakano, Shinichi Uesato & Yoshie Maitani. (2011) Antitumor Effect of Liposomal Histone Deacetylase Inhibitor-Lipid Conjugates in Vitro. Chemical and Pharmaceutical Bulletin 59:11, pages 1386-1392.
Crossref
Crossref
Gonzalo Lopez, Keila Torres, Juehui Liu, Belinda Hernandez, Eric Young, Roman Belousov, Svetlana Bolshakov, Alexander J. Lazar, John M. Slopis, Ian E. McCutcheon, David McConkey & Dina Lev. (2011) Autophagic Survival in Resistance to Histone Deacetylase Inhibitors: Novel Strategies to Treat Malignant Peripheral Nerve Sheath Tumors. Cancer Research 71:1, pages 185-196.
Crossref
Crossref
Takashi Murakami. 2011. Experimental and Applied Immunotherapy. Experimental and Applied Immunotherapy
307
322
.
Joya Chandra & Claudia P. Miller. 2011. New Agents for the Treatment of Acute Lymphoblastic Leukemia. New Agents for the Treatment of Acute Lymphoblastic Leukemia
273
298
.
Patrick Imesch, Daniel Fink & André Fedier. (2010) Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells. Fertility and Sterility 94:7, pages 2838-2842.
Crossref
Crossref
Gesine Bug & Oliver G. Ottmann. (2010) The DAC system and associations with acute leukemias and myelodysplastic syndromes. Investigational New Drugs 28:S1, pages 36-49.
Crossref
Crossref
Xiaoli Ma, Jia Liu, Jiang Wu, Xiyun Yan, Peng Wu, Yong Liu, Shuang Li, Yuan Tian, Yang Cao, Gang Chen, Li Meng, Gang Xu, Shixuan Wang, Yunping Lu, Ding Ma & Jianfeng Zhou. (2010) Synergistic Killing Effect between Vorinostat and Target of CD146 in Malignant Cells. Clinical Cancer Research 16:21, pages 5165-5176.
Crossref
Crossref
Bo Ra You & Woo Hyun Park. (2010) Suberoyl bishydroxamic acid inhibits the growth of A549 lung cancer cells via caspase-dependent apoptosis. Molecular and Cellular Biochemistry 344:1-2, pages 203-210.
Crossref
Crossref
Yi-kang Shi, Zhong-hua Li, Xi-qian Han, Ji-hu Yi, Zhen-hua Wang, Jing-li Hou, Cong-ran Feng, Qing-hong Fang, Hui-hui Wang, Peng-fei Zhang, Feng-shan Wang, Jie Shen & Peng Wang. (2010) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer. Cancer Chemotherapy and Pharmacology 66:6, pages 1131-1140.
Crossref
Crossref
Gregory A. Otterson, Lydia Hodgson, Herbert Pang & Everett E. Vokes. (2010) Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304). Journal of Thoracic Oncology 5:10, pages 1644-1648.
Crossref
Crossref
Ali R. Jazirehi. (2010) Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anti-Cancer Drugs 21:9, pages 805-813.
Crossref
Crossref
Alea A. Mills. (2010) Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nature Reviews Cancer 10:10, pages 669-682.
Crossref
Crossref
Noriyuki Takai & Hisashi Narahara. (2010) Epigenetic Therapy in Human Choriocarcinoma. Cancers 2:3, pages 1683-1688.
Crossref
Crossref
Leonel Maldonado & Mohammad Obaidul Hoque. (2010) Epigenomics and ovarian carcinoma. Biomarkers in Medicine 4:4, pages 543-570.
Crossref
Crossref
Minakshi Nihal, Craig T. Roelke & Gary S. Wood. (2010) Anti-Melanoma Effects of Vorinostat in Combination with Polyphenolic Antioxidant (−)-Epigallocatechin-3-Gallate (EGCG). Pharmaceutical Research 27:6, pages 1103-1114.
Crossref
Crossref
C. Song, A. Kanthasamy, V. Anantharam, F. Sun & A. G. Kanthasamy. (2010) Environmental Neurotoxic Pesticide Increases Histone Acetylation to Promote Apoptosis in Dopaminergic Neuronal Cells: Relevance to Epigenetic Mechanisms of Neurodegeneration. Molecular Pharmacology 77:4, pages 621-632.
Crossref
Crossref
Paul K. Paik & Lee M. Krug. (2010) Histone Deacetylase Inhibitors in Malignant Pleural Mesothelioma: Preclinical Rationale and Clinical Trials. Journal of Thoracic Oncology 5:2, pages 275-279.
Crossref
Crossref
G.F. Davies, A.R. Ross, T.G. Arnason, B.H.J. Juurlink & T.A.A. Harkness. (2010) Troglitazone inhibits histone deacetylase activity in breast cancer cells. Cancer Letters 288:2, pages 236-250.
Crossref
Crossref
Lin Liu, Baoan Chen, Shukui Qin, Suyi Li, Xiangming He, Shaomin Qiu, Wei Zhao & Hong Zhao. (2010) A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells. Biochemical and Biophysical Research Communications 392:2, pages 190-195.
Crossref
Crossref
Noriyuki Takai & Hisashi Narahara. (2010) Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer. Obstetrics and Gynecology International 2010, pages 1-8.
Crossref
Crossref
P Wu, Y Tian, G Chen, B Wang, L Gui, L Xi, X Ma, Y Fang, T Zhu, D Wang, L Meng, G Xu, S Wang, D Ma & J Zhou. (2009) Ubiquitin B: an essential mediator of trichostatin A-induced tumor-selective killing in human cancer cells. Cell Death & Differentiation 17:1, pages 109-118.
Crossref
Crossref
John Patrick Alao. 2009. Checkpoint Controls and Targets in Cancer Therapy. Checkpoint Controls and Targets in Cancer Therapy
123
153
.
Andrew A. LaneBruce A. Chabner. (2009) Histone Deacetylase Inhibitors in Cancer Therapy. Journal of Clinical Oncology 27:32, pages 5459-5468.
Crossref
Crossref
Xiaoli Ma, Quanfu Ma, Jia Liu, Yuan Tian, Beibei Wang, Kathryn M. Taylor, Peng Wu, Daowen Wang, Gang Xu, Li Meng, Shixuan Wang, Ding Ma & Jianfeng Zhou. (2009)
Identification of
LIV1
, a Putative Zinc Transporter Gene Responsible for HDACi-Induced Apoptosis, Using a Functional Gene Screen Approach
. Molecular Cancer Therapeutics 8:11, pages 3108-3116.
Crossref
Crossref
D.S. Mestel, M. Beyer, M. Steinhoff & W. Sterry. (2009) Treatment of Cutaneous Lymphomas: Today and Tomorrow. Actas Dermo-Sifiliográficas 100, pages 18-32.
Crossref
Crossref
Koichi Narita, Takuya Kikuchi, Kazuhiro Watanabe, Toshiya Takizawa, Takamasa Oguchi, Kyosuke Kudo, Keisuke Matsuhara, Hideki Abe, Takao Yamori, Minoru Yoshida & Tadashi Katoh. (2009)
Total Synthesis of the Bicyclic Depsipeptide HDAC Inhibitors Spiruchostatins A and B, 5′′‐
epi
‐Spiruchostatin B, FK228 (FR901228) and Preliminary Evaluation of Their Biological Activity
. Chemistry – A European Journal 15:42, pages 11174-11186.
Crossref
Crossref
Jianqing Lin, Jill Gilbert, Michelle A. Rudek, James A. Zwiebel, Steve Gore, Anchalee Jiemjit, Ming Zhao, Sharyn D. Baker, Richard F. Ambinder, James G. Herman, Ross C. Donehower & Michael A. Carducci. (2009) A Phase I Dose-Finding Study of 5-Azacytidine in Combination with Sodium Phenylbutyrate in Patients with Refractory Solid Tumors. Clinical Cancer Research 15:19, pages 6241-6249.
Crossref
Crossref
Robert P. Whitehead, Cathryn Rankin, Paulo M. G. Hoff, Philip J. Gold, Kevin G. Billingsley, Robert A. Chapman, Lucas Wong, John H. Ward, James L. Abbruzzese & Charles D. Blanke. (2008) Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Investigational New Drugs 27:5, pages 469-475.
Crossref
Crossref
Andreas Lennartsson & Karl Ekwall. (2009) Histone modification patterns and epigenetic codes. Biochimica et Biophysica Acta (BBA) - General Subjects 1790:9, pages 863-868.
Crossref
Crossref
Oronza Antonietta Botrugno, Fabio Santoro & Saverio Minucci. (2009) Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Letters 280:2, pages 134-144.
Crossref
Crossref
Gonzalo Lopez, Juehui Liu, Wenhong Ren, Wei Wei, Suizhao Wang, Guy Lahat, Quan-Sheng Zhu, William G. Bornmann, David J. McConkey, Raphael E. Pollock & Dina C. Lev. (2009) Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma. Clinical Cancer Research 15:10, pages 3472-3483.
Crossref
Crossref
Joya Chandra. (2009) Oxidative Stress by Targeted Agents Promotes Cytotoxicity in Hematologic Malignancies. Antioxidants & Redox Signaling 11:5, pages 1123-1137.
Crossref
Crossref
Adil I. Daud, Jana Dawson, Ronald C. DeConti, Elona Bicaku, Douglas Marchion, Sem Bastien, Frederick A. HausheerIIIIII, Richard Lush, Anthony Neuger, Daniel M. Sullivan & Pamela N. Munster. (2009) Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial. Clinical Cancer Research 15:7, pages 2479-2487.
Crossref
Crossref
Pamela Munster, Douglas Marchion, Elona Bicaku, Mira Lacevic, Jongphil Kim, Barbara Centeno, Adil Daud, Anthony Neuger, Susan Minton & Daniel Sullivan. (2009) Clinical and Biological Effects of Valproic Acid as a Histone Deacetylase Inhibitor on Tumor and Surrogate Tissues: Phase I/II Trial of Valproic acid and Epirubicin/FEC. Clinical Cancer Research 15:7, pages 2488-2496.
Crossref
Crossref
Jin C. Kim, Dae D. Kim, Yoo M. Lee, Tae W. Kim, Dong H. Cho, Moon B. Kim, Seong G. Ro, Seon Y. Kim, Yong S. Kim & Jung S. Lee. (2008) Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. International Journal of Colorectal Disease 24:2, pages 209-218.
Crossref
Crossref
Jin Young SeoYoo Mi LeeDong Hyung ChoSeon Ae RohSeong gu RoYoung Lan HyunSeon Young KimYoug Sung KimTae Won KimSei Hyun AhnJin Cheon Kim. (2009) Comparison between Therapeutic Efficacies of Histone Deacetylase Inhibitors and Established Drug Regimens Against Breast Cancer Cells using the Histoculture Drug Response Assay. Journal of Breast Cancer 12:4, pages 241.
Crossref
Crossref
Chitra V. Kotwaliwale & Sue Biggins. 2009. The Kinetochore:. The Kinetochore:
1
51
.
Rita Scarpelli, Annalise Di Marco, Federica Ferrigno, Ralph Laufer, Isabella Marcucci, Ester Muraglia, Jesus M. Ontoria, Michael Rowley, Sergio Serafini, Christian Steinkühler & Philip Jones. (2008) Studies of the metabolic stability in cells of 5-(trifluoroacetyl)thiophene-2-carboxamides and identification of more stable class II histone deacetylase (HDAC) inhibitors. Bioorganic & Medicinal Chemistry Letters 18:23, pages 6078-6082.
Crossref
Crossref
Min-Jung Lee, Yeong Sang Kim, Shivaani Kummar, Giuseppe Giaccone & Jane B Trepel. (2008) Histone deacetylase inhibitors in cancer therapy. Current Opinion in Oncology 20:6, pages 639-649.
Crossref
Crossref
Johann S. de Bono, Rebecca Kristeleit, Anthony Tolcher, Peter Fong, Simon Pacey, Vasilios Karavasilis, Monica Mita, Heather Shaw, Paul Workman, Stan Kaye, Eric K. Rowinsky, Wynne Aherne, Peter Atadja, Jeffrey W. Scott & Amita Patnaik. (2008) Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors. Clinical Cancer Research 14:20, pages 6663-6673.
Crossref
Crossref
Arun K. Ghosh & Sarang Kulkarni. (2008) Enantioselective Total Synthesis of (+)-Largazole, a Potent Inhibitor of Histone Deacetylase. Organic Letters 10:17, pages 3907-3909.
Crossref
Crossref
Yujun George Zheng, Jiang Wu, Ziyue Chen & Masha Goodman. (2008) Chemical regulation of epigenetic modifications: Opportunities for new cancer therapy. Medicinal Research Reviews 28:5, pages 645-687.
Crossref
Crossref
Andrea Newbold, Ralph K. Lindemann, Leonie A. Cluse, Kate F. Whitecross, Anthony E. Dear & Ricky W. Johnstone. (2008) Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin. Molecular Cancer Therapeutics 7:5, pages 1066-1079.
Crossref
Crossref
Alfonso Duenas-Gonzalez, Myrna Candelaria, Carlos Perez-Plascencia, Enrique Perez-Cardenas, Erick de la Cruz-Hernandez & Luis A. Herrera. (2008) Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors. Cancer Treatment Reviews 34:3, pages 206-222.
Crossref
Crossref
Avigail D. Amsel, Moran Rathaus, Noam Kronman & Haim Y. Cohen. (2008) Regulation of the proapoptotic factor Bax by Ku70-dependent deubiquitylation. Proceedings of the National Academy of Sciences 105:13, pages 5117-5122.
Crossref
Crossref
Marielle Paris, Marina Porcelloni, Monica Binaschi & Daniela Fattori. (2008) Histone Deacetylase Inhibitors: From Bench to Clinic. Journal of Medicinal Chemistry 51:6, pages 1505-1529.
Crossref
Crossref
Nagma KhanMichael JeffersSampath KumarCraig HackettFerenc BoldogNicholai KhramtsovXiaozhong QianEvan MillsStanny C. BerghsNessa CareyPaul W. FinnLaura S. CollinsAnthony TumberJames W. RitchiePeter Buhl Jensen, Henri S. LichensteinMaxwell Sehested. (2007) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochemical Journal 409:2, pages 581-589.
Crossref
Crossref
David Fatkins & Weiping Zheng. (2008) Substituting Nε-thioacetyl-lysine for Nε-acetyl-lysine in Peptide Substrates as a General Approach to Inhibiting Human NAD+-dependent Protein Deacetylases. International Journal of Molecular Sciences 9:1, pages 1-11.
Crossref
Crossref
Li-Ning Xu, Xin Wang & Sheng-Quan Zou. (2008) Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines. World Journal of Gastroenterology 14:16, pages 2578.
Crossref
Crossref
Matthias Körner & Ulrich Tibes. 2008. Progress in Medicinal Chemistry Volume 46. Progress in Medicinal Chemistry Volume 46
205
280
.
Valeria R. Fantin & Victoria M. Richon. (2007) Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications. Clinical Cancer Research 13:24, pages 7237-7242.
Crossref
Crossref
X-J Yang & E Seto. (2007) HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26:37, pages 5310-5318.
Crossref
Crossref
Suzanne A Eccles & Danny R Welch. (2007) Metastasis: recent discoveries and novel treatment strategies. The Lancet 369:9574, pages 1742-1757.
Crossref
Crossref